- Immunome Inc (NASDAQ:IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing.
- IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2.
- Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data.
- The company expects topline data from Phase 1b study in 2H of 2022.
- IMM-BCP-01 is a three-antibody cocktail, with each antibody having a different mechanism of action.
- “Further, as several existing antibody treatments lose their potency against the Omicron subvariants, IMM-BCP-01 continues to retain activity against these variants in preclinical testing, and we believe our cocktail has the potential to play a significant role in managing the pandemic,” stated Purnanand Sarma, President & CEO.
- Price Action: IMNM shares closed at $3.42 on Tuesday.
Here’s How Much $1000 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 20 years by 11.6% on an annualized basis producing an average annual return of 19.59%. Currently, Thermo Fisher Scientific has a market capitalization of $230.17 billion.
